Oncosil will be a run-away success both for patients and shareholders if they:
- can show a viable difference to patient outcomes, either stand-alone or in combo with chemo
- be readily available in Europe and Australasia, multi supply chain and better buying price
- are respected and adopted by decision makers who pay for it
- have a large hospital network that can make the treatment available ( ie training and licensing )
- have a driven and experienced team to drive success
- have a leader / CEO who has the experience and is well networked in the field plus the board
Where are we with this I ask you ?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.020(2.00%) |
Mkt cap ! $14.50M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 99.5¢ | $44.12K | 44.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 968 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 6234 | 1 |
View Market Depth
| Last trade - 15.28pm 25/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |